|
17 Nov 2022 |
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
|
|
17 Nov 2022 |
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
|
|
17 Nov 2022 |
Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines
|
|
15 Nov 2022 |
Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
|
|
15 Nov 2022 |
Daiichi Sankyo Announces Results of Booster Vaccination Trial of Its mRNA COVID-19 Vaccine (DS-5670) in Japan
|
|
12 Nov 2022 |
YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
|
|
10 Nov 2022 |
New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation
|
|
10 Nov 2022 |
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
|
|
08 Nov 2022 |
Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine (HexaPro) Delivered Using High-Density Microarray Patch (HD-MAP)
|
|
07 Nov 2022 |
Blue Lake Biotechnology Announces Positive Interim Phase 1 Data for BLB201 Intranasal RSV Vaccine
|
|
07 Nov 2022 |
Meissa Vaccines Announces Positive Interim Clinical Data for Its Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine Candidate for Infants
|
|
07 Nov 2022 |
Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial
|
|
05 Nov 2022 |
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
|
|
04 Nov 2022 |
Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine
|
|
02 Nov 2022 |
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
|
|
01 Nov 2022 |
Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial
|
|
01 Nov 2022 |
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
|
|
01 Nov 2022 |
Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients
|
|
01 Nov 2022 |
Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19
|
|
27 Oct 2022 |
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
|
|
26 Oct 2022 |
Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines
|
|
26 Oct 2022 |
Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases
|
|
26 Oct 2022 |
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
|
|
24 Oct 2022 |
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
|
|
20 Oct 2022 |
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
|
